Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | CCR3 | P51677 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | F10 | P00742 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4676097 | 0.92 | TSHR (0.50) | ALDH1A1SMN1; SMN2KDM4EKMT2AMEN1 | |
| SCHEMBL4673655 | 0.87 | CCR3 (0.54) | ALDH1A1SMN1; SMN2KMT2ACCR3TSHR | |
| SCHEMBL4674550 | 0.86 | CCR3 (0.49) | KMT2AMEN1CCR3HRH3 | |
| SCHEMBL4679788 | 0.86 | CCR3 (0.54) | ALDH1A1SMN1; SMN2KMT2ACCR3NPSR1 | |
| SCHEMBL4676806 | 0.86 | CCR3 (0.53) | ALDH1A1SMN1; SMN2KDM4EKMT2ACCR3 | |
| SCHEMBL4678302 | 0.85 | CCR3 (0.52) | ALDH1A1KMT2AMEN1CCR3 | |
| SCHEMBL4674120 | 0.84 | CCR3 (0.51) | KMT2ACCR3 | |
| SCHEMBL4677003 | 0.84 | CCR3 (0.51) | SMN1; SMN2CCR3MAPK1TSHRNPSR1 | |
| SCHEMBL4677131 | 0.82 | EPHX2 (0.49) | CCR3 | |
| SCHEMBL4673703 | 0.82 | CCR3 (0.54) | ALDH1A1SMN1; SMN2KDM4ECCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1196404-B1 | PIPERAZINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA UK LTD (GB) | 2008-01-23 | — | — | EP | claimed |
| US-6562825-B1 | For treating inflammatory disease including asthma and allergic diseases, as well as autoimmune pathologies | ASTRAZENECA UK LIMITED (GB) | 2003-05-13 | — | — | US | claimed |
| EP-1196404-B1 | PIPERAZINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA UK LTD (GB) | 2008-01-23 | — | — | EP | disclosed |
| US-6562825-B1 | For treating inflammatory disease including asthma and allergic diseases, as well as autoimmune pathologies | ASTRAZENECA UK LIMITED (GB) | 2003-05-13 | — | — | US | disclosed |
| EP-1196404-A1 | PIPERAZINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Astrazeneca UK Limited (GB) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001002381-A1 | PIPERAZINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA UK LIMITED (GB) | 2001-01-11 | — | — | WO | disclosed |